IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual Meeting
Provided By GlobeNewswire
Last update: May 23, 2024
NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced an upcoming presentation of updated results from its fully enrolled Phase 1 study of INB-200 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 31st - June 4th in Chicago, Illinois. INB-200 is evaluating autologous Drug Resistant Immunotherapy (DeltEx DRI) or chemotherapy resistant gamma-delta T cells as a potential first-line treatment for patients with newly diagnosed glioblastoma multiforme (GBM).
0.2715
-0.01 (-5.07%)
Find more stocks in the Stock Screener
INAB Latest News and Analysis
9 days ago - ChartmillThe trading volume of these stocks is deviating from the norm in today's session.Which stocks have an unusual volume on Thursday?
10 days ago - ChartmillUnusual volume stocks in Wednesday's sessionDiscover the stocks with unexpected trading volume in today's session on the US markets.
11 days ago - ChartmillWhich stocks are moving after the closing bell on Tuesday?Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session.
11 days ago - ChartmillThese stocks are making the most noise in today's session.These stocks are making the most noise in today's session. Stay tuned for the latest updates!
11 days ago - ChartmillTuesday's session: gap up and gap down stocksLet's have a look at the gap up and gap down stocks in today's session.
11 days ago - ChartmillWhich stocks are moving before the opening bell on Tuesday?As the US market prepares to open on Tuesday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
